SafeBeat
SafeBeat is an investigational AI ECG analysis platform that guides cardiac drug initiation and adjustment from a phone.
SafeBeat is worth tracking, not deploying. The workflow it targets — phone-captured ECG guiding drug initiation and titration remotely instead of admitting patients — is a real gap, and the clinician endorsements plus an NIH/NHLBI SBIR supplement and SOC 2 Type 2 suggest the science and the security posture are being taken seriously. But it is investigational-use-only and not for sale, so no clinical team can run it in production today.
Verified 18h ago · liveness 60/100 · cite: rightaichoice.com/tools/safebeat
- Electrophysiologists investigating remote cardiac drug initiation workflows
- Cardiology researchers running AI-guided therapy pilots under an IRB
- Health systems scouting pre-commercial cardiac AI before it clears
- AFib programs looking to cut inpatient monitoring burden
- Clinicians who need a deployable, FDA-cleared product today
- Patients without a compatible FDA-cleared ECG monitoring device
- Emergency cardiac detection or rapid-response alerting
We scan live Reddit threads, YouTube comments, X posts, G2 reviews and other communities — and hand you an honest verdict in under a minute.
- Honest verdict, not marketing
- Real pros & cons from real users
- Attributed quotes with receipts
3 free scans · no card needed
Skip SafeBeat if you need a cleared, patient-ready cardiac monitoring or drug-titration tool this quarter — it is investigational, not for sale, and limited by federal law to investigational use only.
Because SafeBeat relies on third-party mobile ECG, telemetry and implantable monitors, the device and monitoring-service costs sit with those vendors and are not part of SafeBeat itself
No pricing is published anywhere in the material we reviewed, so budget fit cannot be assessed. Two practical comparisons for planning: cleared diagnostic AI-ECG tools are sold today on per-study or subscription models, while investigational platforms like SafeBeat are typically funded through research grants or pilot budgets rather than clinical operating funds — so the near-term comparison is your research budget, not your cardiology software line.
In short
SafeBeat — SafeBeat is an investigational AI ECG analysis platform that guides cardiac drug initiation and adjustment from a phone. Best for Electrophysiologists investigating remote cardiac drug initiation workflows, Cardiology researchers running AI-guided therapy pilots under an IRB, Health systems scouting pre-commercial cardiac AI before it clears. Contact Sales pricing.
What's new in SafeBeat
Checked 9 days agoAcross the latest 3 updates: 3 news mentions.
SafeBeat Achieves SOC 2 Type 2 Compliance
SafeBeat announced SOC 2 Type 2 compliance, confirming the security and privacy controls behind its operations — the report health systems typically request during vendor security review.
SafeBeat Receives Supplement Award for UCSF Phase II SBIR Grant
SafeBeat received a supplement award from NIH/NHLBI for its Phase II SBIR grant, in collaboration with UCSF, extending funding for its AI-guided cardiac therapeutic work.
SafeBeat Presents Three New Abstracts at AF Symposium
SafeBeat presented three abstracts on AI-ECG innovation at the annual AF Symposium in Boston, adding peer-facing evidence to its clinical development story.
Viability Score
How well maintained and how widely used is SafeBeat? Built from what the vendor actually publishes (docs, changelog, tutorials, integrations, pricing), whether the site is live, and how much real users discuss it. How we calculate this
Last calculated: October 2026
How we score →Key Features
- AI-based ECG interpretation for cardiac assessment
- Guidance for cardiac medication initiation and adjustment
- Remote therapeutic monitoring workflow guided from a smartphone
- Explainable AI outputs designed for clinician review
- Customizable, patient-specific treatment steps
- Ingests mobile ECG, mobile cardiac telemetry, and implantable cardiac monitor data
- Cloud dashboard for multi-patient review from a phone
- Alert-triage design intended to reduce clinician alert fatigue
- Patient symptom logging
- API for EHR integration
- Software licensed to third parties to power their own products
- SOC 2 Type 2 compliant operations
- HIPAA-compliant data handling
- All software streamlined for use from a mobile phone
About SafeBeat
SafeBeat is an investigational AI platform for cardiac care that goes past diagnostics into treatment. It runs proprietary machine learning algorithms over ECG data captured on third-party FDA-cleared cardiac monitors — mobile ECG, mobile cardiac telemetry, and implantable cardiac monitors — and pushes results to a cloud dashboard built for phone-first review. The intended audience is electrophysiologists, cardiologists, and AFib program leads who want to start or titrate cardiac medications remotely instead of admitting patients for in-hospital monitoring. The platform pairs explainable AI outputs with customizable, patient-specific treatment steps, so a clinician sees both the rhythm interpretation and the next action. Patient symptom logging runs alongside clinician review, and the alert-triage design is aimed squarely at the alert fatigue problem that plagues multi-patient monitoring. SafeBeat says it is making its ECG-analysis software available to power other companies' products, an API path toward EHR integration. Development momentum has continued: SafeBeat announced SOC 2 Type 2 compliance in August 2026, received an NIH/NHLBI supplement award to its UCSF-collaborated Phase II SBIR grant, and presented three AI-ECG abstracts at the AF Symposium. Testimonials on the site come from named cardiologists at Cedars-Sinai, Stanford, UCSF, and the San Francisco VA. The caution on the site is unambiguous — product under development, not currently for sale, and Limited by Federal (or United States) Law to Investigational Use Only. That puts SafeBeat in a different category from cleared remote monitoring and diagnostic ECG products you can buy today.
Behind the Verdict
The interesting thing about SafeBeat isn't the ECG interpretation — plenty of companies do that. It's the claim that analysis should feed treatment: initiate this drug, adjust that dose, without admitting the patient. That is where the money and the risk sit, and it's why the endorsements name people like Sanjiv Narayan at Stanford and Melvin Scheinman at UCSF rather than anonymous pilot customers. Pick this if you are an electrophysiologist or AFib program lead who wants to shape a remote drug-initiation workflow early, or a health system scouting pre-commercial cardiac AI before it hits the market. Research groups running AI-guided therapy pilots under UCSF's SBIR collaboration are the natural fit. The SOC 2 Type 2 report from August 2026 gives your security review something concrete to work with. Pass if you need a cleared product in production this quarter. Nothing on the site claims FDA clearance, and the caution states the product is under development, not for sale, and limited to investigational use. Emergency detection and rapid-response alerting are out of scope too, as is any workflow where the patient doesn't already have a compatible monitoring device. In practice the closest alternatives are the device makers themselves. iRhythm's Zio and implantable monitors from Medtronic and Abbott already deliver cleared rhythm data; what they don't do is bundle medication titration guidance into a phone-first clinician dashboard, which is the slice SafeBeat is going after. If a health system already owns that monitoring stack, SafeBeat is an add-on argument, not a replacement one. Where it bites: evaluating an investigational system takes clinical champion time, an IRB path, and patience. The third-party licensing play — powering other companies' products — is
Researching SafeBeat? Get your full AI stack in 60 seconds.
Free, no signup — tell us your goal and get tools matched to your budget & existing stack.
Real-world workflow fit
Concrete scenarios for the personas SafeBeat actually fits — and what changes day-one when you adopt it.
You run an AFib drug-initiation pilot and want to monitor patients remotely instead of admitting them for observation. Patients wear a compatible mobile ECG or implantable monitor; SafeBeat's dashboard surfaces rhythm interpretation and a patient-specific treatment step for you to review on your phone.
Outcome: You see structured, explainable ECG findings and the next care step in one place without triaging a raw alert stream — subject to the pilot's IRB approval and SafeBeat's investigational-use status.
You need standardized ECG capture and consistent AI summarization across a cohort. SafeBeat ingests data from third-party cleared monitors and routes it to a cloud dashboard, with an API for pulling results into your EHR or study database.
Outcome: A uniform data-collection path across mobile ECG, telemetry and implantable monitors, reducing the manual reconciliation work of multi-device studies.
You are building a shortlist of pre-commercial cardiac platforms to evaluate over the next year and need to gauge security posture and clinical credibility before committing staff time.
Outcome: SafeBeat's August 2026 SOC 2 Type 2 announcement and its NIH/NHLBI SBIR supplement with UCSF give you concrete diligence items, so the evaluation can proceed without a full technical deep-dive yet.
Use Cases
- Remote anticoagulation management for AFib patients
- Outpatient cardiac drug initiation and titration without inpatient monitoring
- AI-summarized arrhythmia reports for electrophysiology review
- Early arrhythmia detection via mobile cardiac telemetry
- Standardized ECG data collection in clinical research and trials
- AFib program pilots aiming to reduce inpatient monitoring burden
Models Under the Hood
as of 2026-09-25
Limitations
- SafeBeat is under development and not currently for sale; the site states it is Limited by Federal (or United States) Law to Investigational Use Only.
- No FDA clearance or authorization for the software is claimed in the material reviewed.
- Because the platform's core value is therapeutic guidance — medication initiation and adjustment — rather than simple diagnostic alerting, the regulatory bar it must clear is higher, and clearance timing is not stated anywhere we could see.
- SafeBeat does not manufacture monitors; it depends on third-party FDA-cleared mobile ECG, mobile cardiac telemetry and implantable cardiac monitor devices, so utility is bounded by what those devices capture.
- Features and integrations may change as the product evolves.
- This is a remote therapeutic monitoring workflow, not an emergency detection system.
as of 2026-09-23
Verification history
We have re-verified SafeBeat 9 times since . Each pass re-reads the vendor's own pages and re-checks every listed field against that evidence; passes where nothing had changed are marked as such.
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-checked, vendor evidence unchanged
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
- — re-verified summary, description, our verdict, our analysis, pricing model, pricing tiers, features, integrations, who it suits, who should skip it
Showing the 6 most recent of 9 verification passes.
Free to cite with attribution — this page re-verifies continuously.
Where the pricing makes sense
The company stage and team size where SafeBeat's pricing actually pencils out — and where peers do it cheaper.
No pricing is published anywhere in the material we reviewed, so budget fit cannot be assessed. Two practical comparisons for planning: cleared diagnostic AI-ECG tools are sold today on per-study or subscription models, while investigational platforms like SafeBeat are typically funded through research grants or pilot budgets rather than clinical operating funds — so the near-term comparison is your research budget, not your cardiology software line.
Setup time & first value
How long it actually takes to get something useful out of SafeBeat — broken out by persona, not the marketing-page minute.
For an electrophysiology pilot: expect weeks, not hours — you need compatible third-party monitors in patients' hands, IRB approval for investigational use, and an EHR integration path before the first patient is enrolled. For a research study: similar, gated by device sourcing and protocol approval. For an innovation-team scouting exercise: an afternoon reading the site's clinical testimonials
Switching to or from SafeBeat
How to bring data in from common predecessors and how to get it back out — written for the switcher, not the buyer.
- →From inpatient drug-initiation monitoring: shift observation to outpatient monitoring using compatible mobile ECG or telemetry devices feeding SafeBeat, subject to IRB approval
- →From manual ECG review workflows: route third-party monitor data into SafeBeat's dashboard for AI interpretation and patient-specific treatment steps
- →From spreadsheet-based research ECG tracking: use SafeBeat's cloud dashboard and EHR API to standardize collection across devices
- ↗To cleared diagnostic AI-ECG tools: if you need production use before SafeBeat's regulatory path completes, move to an FDA-cleared ECG analysis product
- ↗To device-native monitoring platforms: if your KardiaMobile, Zio, Reveal LINQ or Confirm Rx vendor ships comparable AI interpretation, you can consolidate on their software
Integrations
Resources & Guides
Tutorials & Learning
YouTube returned 6 videos for “SafeBeat”, and we withheld 6: 6 could not be judged, because “SafeBeat” is a single word that other videos use for other things. We are showing none, because we could not prove any of them are about SafeBeat.
Official links
Tools that pair well with SafeBeat
Common stack mates teams adopt alongside SafeBeat, with the specific reason each pairing earns its keep.
PathAI
PathAI is an enterprise digital pathology platform for diagnostic accuracy and biopharma drug development.
Viz.ai
Viz.ai is an enterprise AI care coordination platform that auto-detects stroke, cardiac, vascular, and pulmonary disease from imaging and alerts the right
InVision Medical Technology
FDA-cleared echo AI that automates LVEF, screens for cardiac amyloidosis, and now carries a Medicare NTAP.
Featured Head-to-Head Comparisons
Safebeat vs Isomorphic Labs
Isomorphic Labs leads in AI-driven drug discovery with DeepMind backing and major pharma partnerships, but only for large-scale collaboration. SafeBeat targets a narrower cardiac niche, offering practical remote monitoring but remains in investigational stage. Choose Isomorphic for drug R&D; choose SafeBeat for cardiac therapeutic management if approved.
Safebeat vs Codametrix
CodaMetrix is the clear choice for large health systems needing proven, enterprise-scale coding automation with tangible ROI and industry validation. SafeBeat has potential for remote cardiac management, but remains investigational with no FDA clearance or commercial availability, making it unsuitable for production use today.
Safebeat vs Rapidsos
RapidSOS and SafeBeat do not compete directly. RapidSOS is a mature, widely deployed emergency response platform for public safety and enterprises, while SafeBeat is an investigational cardiac therapeutic tool for clinicians. For emergency response, choose RapidSOS; for remote cardiac monitoring guidance, consider SafeBeat once it is commercially available.
Alternatives to SafeBeat
View allPathAI
PathAI is an enterprise digital pathology platform for diagnostic accuracy and biopharma drug development.
Viz.ai
Viz.ai is an enterprise AI care coordination platform that auto-detects stroke, cardiac, vascular, and pulmonary disease from imaging and alerts the right
InVision Medical Technology
FDA-cleared echo AI that automates LVEF, screens for cardiac amyloidosis, and now carries a Medicare NTAP.
Frequently Asked Questions
Categories
Best-of guides
Used SafeBeat? Help shape our editorial sentiment research.